PRESENTATION
Q1 2022 — Results presentation
Q1 2022PDF · 19 pages2.6 MB
1 -- 1 of 19 -- 1st Quarter 2022 Earnings Call April 19, 2022 -- 2 of 19 -- Cautionary Note on Forward-looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; the New Consumer Health Company’s ability to succeed as a standalone publicly traded company; and risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Cautionary Note on Non-GAAP Financial Measures This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com/sales-earnings.cfm. 3 -- 3 of 19 -- Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA discovered using MorphoSys AG antibody technology Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL CONSTA developed in collaboration with Alkermes, Inc. Infectious Diseases PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at the U.S. Department of Health and Human Services (HHS) Cardiovascular/ Metabolism/Other INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG; PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx Oncology IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S, BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; cilta-cel licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, lazertinib licensed from Yuhan Corporation, DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs, ENHANZE platform licensed from Halozyme Therapeutics, Inc. Pulmonary Hypertension UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan Global Public Health Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C.. The initial work on Ebola was conducted which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center (VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C. Strategic Partnerships, Collaborations & Licensing Arrangements 4 During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships: -- 4 of 19 -- Enterprise Highlights Sales Performance and Earnings Review Capital Allocation and Guidance Q&A 5 Agenda 1 2 3 4 Ashley McEvoy Executive Vice President Worldwide Chairman, MedTech Thibaut Mongon Executive Vice President Worldwide Chairman, Consumer Health Jennifer Taubert Executive Vice President Worldwide Chairman, Pharmaceuticals Joseph J. Wolk Executive Vice President Chief Financial Officer Jessica Moore Vice President Investor Relations -- 5 of 19 -- Regional Sales Results Q1 2022 Q1 2021 % CHANGE Reported Operational1 U.S. $11.4 $11.1 2.7% 2.7% Europe 6.0 5.4 11.3 19.5 Western Hemisphere (ex U.S.) 1.5 1.4 4.1 5.1 Asia-Pacific, Africa 4.5 4.4 3.1 6.6 International 12.0 11.2 7.2 12.6 Worldwide (WW) $23.4 $22.3 5.0% 7.7% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding 1st Quarter 2022 Sales Dollars in Billions 6 -- 6 of 19 -- 3.1%; 6.2%1 Q1 2022 Q1 2021 $2.67 $2.59 1st Quarter 2022 Financial Highlights Dollars in Billions, except EPS Reported %; Operational %1 7 Sales Adjusted Earnings2 Adjusted EPS2 5.0%; 7.7%1 $23.4 $22.3 GAAP Earnings (16.9)% $5.1 $6.2 3.0% Q1 2022 Q1 2021 GAAP EPS (16.8)% $1.93 $2.32 Q1 2022 Q1 2022 Q1 2021 Q1 2021 Q1 2022 Q1 2021 $7.1 $6.9 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website -- 7 of 19 -- OTC $1,461 Skin Health/Beauty $1,012 Oral Care $366 Baby Care $355 Women's Health $228 Wound Care/Other $164 $3,586 (1.5)%, 0.8% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Consumer Health Highlights – 1st Quarter 2022 Solid adjusted operational growth2 driven by OTC 8 Key Drivers of Operational Performance1,3 OTC3 • Growth driven by increased U.S. and ASPAC adult and pediatric fever incidences (TYLENOL & MOTRIN) coupled with EMEA category recovery for Cough & Cold and Digestive Health, as well as U.S. market and share gains across multiple brands (TYLENOL, MOTRIN, IMODIUM & PEPCID) Skin Health/ Beauty • Decline driven by supply constraints, DR. CI LABO - Sedona divestiture in ASPAC, competitive pressures, and the negative impact of reserves true-up outside the U.S., partially offset by U.S. category recovery and strength in LATAM and ASPAC Oral Care • Decline driven by strategic SKU rationalization in the U.S. and lapping prior year COVID-19 related increased demand outside the U.S. Baby Care • Decline driven by supply constraints in the U.S. and EMEA, as well as the negative impact of reserves true-up outside the U.S. Women’s Health • Growth driven by EMEA due to increased stocking and LATAM due to price increases Wound Care/Other • Decline driven by professional tape divestiture along with comparison to prior year COVID-19 related positive impacts for NEOSPORIN in the U.S. and BAND-AID® Brand Adhesive Bandages outside the U.S. This decline was partially offset by U.S. BAND-AID® Brand Adhesive Bandages increased promotions and innovation. Adjusted Operational Sales2,3: WW 1.6%, U.S. (3.2)%, Int’l 5.3% Reported3: WW (1.5)%, U.S. (3.4)%, Int’l 0.0% Operational1,3: WW 0.8%, U.S. (3.4)%, Int’l 4.1% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website 3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes in their respective regions; Note: Values may not add due to rounding 14.8%, 17.1% 2.6%, 8.3% (7.4)%, (7.2)% (8.6)%, (6.4)% (12.2)%, (10.2)% (13.0)%, (11.0)% 3 -- 8 of 19 -- Key Drivers of Operational Performance1,3 Immunology • Growth driven by continued strong uptake of STELARA in Crohn’s Disease and Ulcerative Colitis, partially offset by share declines in Psoriasis / Psoriatic Arthritis • Strength in TREMFYA in Psoriasis and uptake in Psoriatic Arthritis • REMICADE decline due to biosimilar competition Infectious Diseases3 • Growth driven by the contribution of the COVID-19 vaccine • Partially offset by increased competition for PREZISTA/PREZCOBIX/REZOLSTA and PREZISTA OUS LOE Neuroscience3 • Paliperidone long-acting injectables growth due to strength of INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA from patient mix, new patient starts and persistency, as well as the launch of INVEGA HAFYERA Oncology • DARZALEX increase driven by share gains in all regions, continued strong market growth and solid uptake of the subcutaneous formulation • Continued strong global launch uptake of ERLEADA • IMBRUVICA maintained its market leadership position but declined worldwide due to competitive pressures from novel oral agents. U.S. decline partially offset by growth in all regions outside of the U.S. Cardiovascular/ Metabolism/ Other (CVM/Other)3 • Decline driven by XARELTO due to a net unfavorable prior period price adjustment and higher cost for patient access, partially offset by demand and market growth • INVOKANA/INVOKAMET decline due to continued share erosion Pulmonary Hypertension (PH) • Growth driven by strong demand and share gains from OPSUMIT and UPTRAVI, partially offset by COVID-19 related market constraints, as well as entrants in Other Pulmonary Hypertension Adjusted Operational Sales2,3: WW 9.3%, U.S. 2.9%, Int’l 16.7% Immunology $4,119 Infectious Diseases $1,297 Neuroscience $1,741 Oncology $3,950 CVM/Other $910 PH $852 $12,869 6.3%, 9.3% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Pharmaceutical Highlights – 1st Quarter 2022 9 Reported3: WW 6.3%, U.S. 2.9%, Int’l 10.3% Operational1,3: WW 9.3%, U.S. 2.9%, Int’l 16.7% (12.8)%, (11.9)% (1.1)%, 1.2% 10.6%, 14.9% 1.5%, 5.0% 30.0%, 33.1% 5.2%, 7.5% Continued above-market performance driven by Oncology, Immunology, and Neuroscience 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website 3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes in their respective regions; Note: Values may not add due to rounding 3 3 3 -- 9 of 19 -- Orthopaedics $2,188 Surgery $2,434 Vision $1,257 Interventional Solutions $1,092 $6,971 5.9%, 8.5% WW Sales $MM ■ Reported Growth ■ Operational Growth1 MedTech Highlights – 1st Quarter 2022 Growth driven by COVID-19 market recovery, driving market expansion, and innovation 10 Reported: WW 5.9%, U.S. 5.6%, Int’l 6.3% Operational1: WW 8.5%, U.S. 5.6%, Int’l 11.1% Key Drivers of Operational Performance1 Interventional Solutions • Market recovery, success of new products (VIZIGO, CARTO and SMARTTOUCH) and commercial strategies continuing to enhance global leadership Orthopaedics • Hips: Growth from market recovery, strength of the portfolio (ACTIS stem and enabling technologies KINCISE & VELYS Hip Navigation), and momentum in the U.S. Ambulatory Surgery Center channel • Trauma: Growth driven by global market recovery and uptake of new products (Cannulated Compression Headless Screws, Advanced Nailing Systems and FIBULINK) • Knees: Growth due to market recovery, momentum in the U.S. Ambulatory Surgery Center channel, and new products (ATTUNE Revision, Cementless Mobile Bearing & portfolio pull through related to the launch of the VELYS Robotic Assisted Solution) • Spine, Sports & Other: Recovery across most specialties, new products in Sports, Spine & VELYS Digital Solutions, and prior year China distribution channel change partially offset by market softness and competitive pressures in Spine • Spine: WW: ~(3%), U.S.: ~(11%), OUS ~+9% Surgery • Advanced: • Endocutters: ~+3% Driven by market recovery, commercial activities to expand access, and new products (ECHELON Staple Line Reinforcement) aided by a reclass from General Surgery ~+200 bps partially offset by COVID-19 market slow down in the Asia Pacific region and competitive pressures in the U.S. • Biosurgery: ~+10% Market recovery and share momentum driven by market expansion efforts and success of new products (VISTASEAL & SURGICEL POWDER) • Energy: ~FLAT with market recovery and new product penetration (ENSEAL X1 Curved & HARMONIC 1100) mostly offset by COVID-19 market slow downs in ASPAC • General: Growth primarily driven by market recovery, strength of the Suture portfolio, and technology penetration (Barbed Sutures & Topical Skin Adhesives) Vision • Contact Lenses/Other: Growth driven primarily by market recovery and new products (ACUVUE OASYS Multifocal and ACUVUE DEFINE Fresh). U.S. benefit related to current year forward buy ahead of a list price increase primarily offset by the negative impact from prior year stocking • Surgical: Growth primarily driven by Cataract market recovery and market share momentum driven by uptake of recently launched products (TECNIS EYHANCE and TECNIS SYNERGY) Adjusted Operational Sales2: WW 8.6%, U.S. 5.7%, Int’l 11.2% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding; The MedTech segment was previously referred to as the Medical Devices segment 15.1%, 17.4% 9.8%, 13.9% 3.5%, 5.6% 2.6%, 5.0% -- 10 of 19 -- 2022 2021 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $23,426 100.0 $22,321 100.0 5.0 Cost of products sold 7,598 32.4 7,063 31.7 7.6 Gross Profit 15,828 67.6 15,258 68.3 3.7 Selling, marketing and administrative expenses 5,938 25.4 5,432 24.3 9.3 Research and development expense 3,462 14.8 3,178 14.2 8.9 In-process research and development 610 2.6 - - Interest (income) expense, net (12) (0.1) 48 0.2 Other (income) expense, net (102) (0.4) (882) (3.9) Restructuring 70 0.3 53 0.2 Earnings before provision for taxes on income 5,862 25.0 7,429 33.3 (21.1) Provision for taxes on income 713 3.0 1,232 5.5 (42.1) Net Earnings $5,149 22.0 $6,197 27.8 (16.9) - Net earnings per share (Diluted) $1.93 $2.32 (16.8) Average shares outstanding (Diluted) 2,666.5 2,672.7 Effective tax rate 12.2% 16.6% . Adjusted earnings before provision for taxes and net earnings1 Earnings before provision for taxes on income $8,218 35.1 $8,291 37.1 (0.9) Net earnings $7,129 30.4 $6,924 31.0 3.0 Net earnings per share (Diluted) $2.67 $2.59 3.1 Effective tax rate 13.3% 16.5% Condensed Consolidated Statement of Earnings 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 11 1st Quarter 2022 (Unaudited; Dollar and Shares in Millions Except Per Share Figures) -- 11 of 19 -- 2022 2021 Adjusted Income Before Tax by Segment1 1st Quarter 2022 12 Pharmaceutical MedTech Consumer Health Expenses Not Allocated to Segments 1Q 2022 1Q 2021 Pharmaceutical3 44.1% 45.5% MedTech 27.0% 30.6% Consumer Health3 22.1% 26.8% Total 35.1% 37.1% % to Sales ($0.2) ($0.1) $8.3B $5.5 $1.0 $8.2B $5.6 $1.9 $0.8 2,3 $2.0 1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 2 Estimated as of 4/19/2022 3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes in their respective regions 3 -- 12 of 19 -- Joseph J. Wolk Executive Vice President, Chief Financial Officer -- 13 of 19 -- Notable Announcements in 1st Quarter 20221 Pharmaceutical • Regulatory Decisions: – U.S. FDA Approves CARVYKTI (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma – U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment – U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen2 – U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment • Regulatory Submissions: – Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Bispecific Antibody Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma – Janssen Seeks Approval of a New Indication for IMBRUVICA (ibrutinib) for Use in Patients with Untreated Mantle Cell Lymphoma • Other: – Janssen Presents New Data Demonstrating the Combination of Niraparib and Abiraterone Acetate Plus Prednisone Significantly Improved Radiographic Progression-Free Survival as a First-Line Therapy in Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer – Janssen Initiates First-of-its-Kind Clinical Study to Bridge Critical Gaps in Care for People of Color with Moderate to Severe Plaque Psoriasis MedTech • Other: – DePuy Synthes Further Reimagines Knee Restoration with the Addition of Two New Innovations to the ATTUNE Knee Portfolio Enterprise • Other: – Johnson & Johnson Statement on Nationwide Opioid Settlement Agreement – Johnson & Johnson Statement on War in Ukraine 14 1 These developments and all other news releases are available online in the Investors section of the company’s website at news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com 2 Subsequent to the quarter -- 14 of 19 -- Capital Allocation Strategy Capital Allocation Organic growth business needs Free cash flow1 Priorities are clear and remain unchanged Competitive dividends Share repurchases HIGHER PRIORITY LOWER PRIORITY Investment in M&A Dollars in Billions Q1 2022 Cash and Marketable Securities $30 Debt ($33) Net Debt ($3) Free Cash Flow1,2 ~$3.4 Q1 2022: $3.5B invested in R&D $2.8B in dividends paid to shareholders Note: values may have been rounded 1 Non-GAAP measure; cash flow from operations less CAPEX 2 Estimated as of April 19, 2022. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings 15 -- 15 of 19 -- 1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items 2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses 3 Euro Average Rate: April 2022 = $1.09; Euro Spot Rate: April 2022 = $1.08 6 Excludes COVID-19 Vaccine Note: Percentages may be rounded. 16 April January Comments Adjusted Operational Sales1,2,6 6.5% - 7.5% 6.5% - 7.5% Maintain Operational Sales2,6 $97.3B - $98.3B 6.5% - 7.5% $97.3B - $98.3B 6.5% - 7.5% Maintain Estimated Reported Sales3,6 $94.8B - $95.8B 3.8% - 4.8% $95.9B - $96.9B 5.0% - 6.0% Incremental FX ($1.1B) Adjusted Pre-Tax Operating Margin4,5 ~50 bps improvement ~50 bps improvement Maintain Net Other Income4 $1.2 - $1.4 billion $1.2 - $1.4 billion Maintain Net Interest Expense / (Income) $0 - $100 million $0 - $100 million Maintain Effective Tax Rate4 15.5% - 16.5% 15.5% - 16.5% Maintain Adjusted EPS (Operational)2,4 $10.60 - $10.80 8.2% - 10.2% $10.60 - $10.80 8.2% - 10.2% Maintain Adjusted EPS (Reported)3,4 $10.15 - $10.35 3.6% - 5.6% $10.40 - $10.60 6.1% - 8.2% Incremental FX ($0.25) 2022 P&L Guidance Company maintains Adjusted Operational EPS; suspends guidance for COVID-19 Vaccine sales -- 16 of 19 -- 17 2022 Sales Considerations Consumer Health • Anticipate continued market recovery and competitive momentum as year progresses with continued growth from major prior year launches • Strong market recovery in second quarter of 2021 • Continue to monitor COVID-19 dynamics MedTech • Anticipate external supply constraints to continue throughout year, with lessened impact in the second half, primarily in Skin Health / Beauty • Expect the second half of 2022 to outperform the first half Pharmaceutical 1 Non-GAAP measure; excludes acquisitions and divestitures 4 Excludes COVID-19 Vaccine 2 Non-GAAP measure; excludes the impact of translational currency Note: Percentages may be rounded 3 Euro Average Rate: April 2022 = $1.09; Euro Spot Rate: April 2022 = $1.08 Phasing Considerations by Segment • Continue to anticipate another year of above-market adjusted operational sales growth • Relatively consistent growth throughout remainder of the year April January Adjusted Operational Sales1,2,4 6.5% - 7.5% 6.5% - 7.5% Operational Sales2,4 $97.3B - $98.3B 6.5% - 7.5% $97.3B - $98.3B 6.5% - 7.5% Estimated Reported Sales3,4 $94.8B - $95.8B 3.8% - 4.8% $95.9B - $96.9B 5.0% - 6.0% Excludes COVID-19 Vaccine sales -- 17 of 19 -- Q&A Jennifer Taubert Executive Vice President Worldwide Chairman, Pharmaceuticals Executive Vice President Worldwide Chairman, MedTech Ashley McEvoy Joseph J. Wolk Executive Vice President, Chief Financial Officer Thibaut Mongon Executive Vice President Worldwide Chairman, Consumer Health -- 18 of 19 -- -- 19 of 19 --